Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$17.27−0.82 (-4.53%)
Close on Nov 16, 2026Market cap $3.78BP/E –Yield –
Relay Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Relay Therapeutics's total assets was $967.46M at Jun 30, 2026. For fiscal 2025 it was $621.33M, down 28.7% from the year before. The highest annual figure on record is $1.10B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $621.33M | -28.7% |
| FY2024 | Dec 31, 2024 | $871.30M | +3.2% |
| FY2023 | Dec 31, 2023 | $843.98M | -23.3% |
| FY2022 | Dec 31, 2022 | $1.10B | +9.1% |
| FY2021 | Dec 31, 2021 | $1.01B | +26.1% |
| FY2020 | Dec 31, 2020 | $799.83M | +103.5% |
| FY2019 | Dec 31, 2019 | $393.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $967.46M | +32.7% |
| Q1 FY2026 | Mar 31, 2026 | $699.61M | -12.5% |
| Q4 FY2025 | Dec 31, 2025 | $621.33M | -28.7% |
| Q3 FY2025 | Sep 30, 2025 | $670.00M | -28.0% |
| Q2 FY2025 | Jun 30, 2025 | $728.84M | -5.7% |
| Q1 FY2025 | Mar 31, 2025 | $799.36M | -5.0% |
| Q4 FY2024 | Dec 31, 2024 | $871.30M | +3.2% |
| Q3 FY2024 | Sep 30, 2024 | $930.12M | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | $772.55M | -19.7% |
| Q1 FY2024 | Mar 31, 2024 | $841.44M | -18.9% |
| Q4 FY2023 | Dec 31, 2023 | $843.98M | -23.3% |
| Q3 FY2023 | Sep 30, 2023 | $906.96M | -22.4% |
| Q2 FY2023 | Jun 30, 2023 | $962.02M | +8.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.04B | +9.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.10B | +9.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.17B | +74.0% |
| Q2 FY2022 | Jun 30, 2022 | $889.42M | +24.5% |
| Q1 FY2022 | Mar 31, 2022 | $949.88M | +23.1% |
| Q4 FY2021 | Dec 31, 2021 | $1.01B | +26.1% |
| Q3 FY2021 | Sep 30, 2021 | $671.62M | -10.7% |
| Q2 FY2021 | Jun 30, 2021 | $714.40M | +105.3% |
| Q1 FY2021 | Mar 31, 2021 | $771.35M | +96.2% |
| Q4 FY2020 | Dec 31, 2020 | $799.83M | – |
| Q3 FY2020 | Sep 30, 2020 | $751.68M | – |
| Q2 FY2020 | Jun 30, 2020 | $348.04M | – |
| Q4 FY2019 | Dec 31, 2019 | $393.07M | – |
See a number that looks wrong?